The causes of encephalitis are numerous, and extensive investigations for infectious agents and other etiologies are often negative. The discovery that many of these encephalitis are immune mediated has changed the approach to the diagnosis and treatment of these disorders. Moreover, the broad spectrum of symptoms including, psychosis, catatonia, alterations of behavior and memory, seizures, abnormal movements, and autonomic dysregulation usually requires a multidisciplinary treatment approach. This review focuses in several forms of encephalitis that occur in children, and for which an autoimmune etiology has been demonstrated (eg, anti-N-methyl-d-aspartate receptor encephalitis) or is strongly suspected (eg, Rasmussen encephalitis, limbic encephalitis, opsoclonus-myoclonus). The authors also review several disorders that may be immune mediated, such as the rapid onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD) syndrome and some encephalopathies with fever and status epilepticus. Recognition of novel immune-mediated encephalitis is important because some of these disorders are highly responsive to immunotherapy.
GableMSGavaliSRadnerA. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis. 2009;28:1421–1429.
2.
LancasterEMartinez-HernandezEDalmauJ. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77:179–189.
3.
DalmauJGleichmanAJHughesEG. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–1098.
4.
GranerodJAmbroseHEDaviesNW. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10:835–844.
5.
GableMSSheriffHDalmauJTilleyDHGlaserCA. The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54:899–904.
6.
DalmauJLancasterEMartinez-HernandezERosenfeldMRBalice-GordonR. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
7.
IraniSRBeraKWatersP. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(pt 6):1655–1667.
8.
TitulaerMJMcCrackenLGabilondoI et al. Clinical Features, Treatment and outcome of 500 patients with anti-NMDA receptor encephalitis [abstract]. Neurology2012;78 (meeting abstracts 1), PL01.001.
9.
FloranceNRDavisRLLamC. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11–18.
10.
LucaNDaengsuwanTDalmauJ. Anti-N-methyl-d-aspartate receptor encephalitis: a newly recognized inflammatory brain disease in children. Arthritis Rheum. 2011;63:2516–2522.
11.
SchmittSEPargeonKFrechetteESHirschLJDalmauJFriedmanD. “Extreme delta brush”: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. In press.
PrussHDalmauJHarmsL. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology. 2010;75:1735–1739.
14.
FrechetteESZhouLGalettaSLChenLDalmauJ. Prolonged follow-up and CSF antibody titers in a patient with anti-NMDA receptor encephalitis. Neurology. 2011;76(7 suppl 2):S64–S66.
15.
HughesEGPengXGleichmanAJ. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30:5866–5875.
16.
IizukaTSakaiFIdeT. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology. 2008;70:504–511.
17.
IshiuraHMatsudaSHigashiharaM. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology. 2008;71:1921–1923.
18.
Wong-KisielLCJiTRenaudDL. Response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis. Neurology. 2010;74:1550–1551.
19.
KashyapePTaylorENgJKrishnakumarDKirkhamFWhitneyA. Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with cyclophosphamide: the need for early aggressive immunotherapy in tumour negative paediatric patients. Eur J Paediatr Neurol. 2012;16:74–78.
20.
KayserMSKohlerCGDalmauJ. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry. 2010;167:1039–1050.
21.
ThamSLKongKH. A case of anti-NMDAR (N-methyl-D-aspartate receptor) encephalitis: A rehabilitation perspective. NeuroRehabilitation. 2012;30:109–112.
22.
HoutrowAJBhandalMPratiniNRDavidsonLNeufeldJA. The rehabilitation of children with anti-N-methyl-d-aspartate-receptor encephalitis: a case series. Am J Phys Med Rehabil. 2012;91:435–441.
23.
AlexopoulosHKosmidisMLDalmauJDalakasMC. Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. J Neurol. 2011;258:1568–1570.
24.
SansingLHTuzunEKoMWBacconJLynchDRDalmauJ. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol. 2007;3:291–296.
25.
GultekinSHRosenfeldMRVoltzREichenJPosnerJBDalmauJ. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(pt 7):1481–1494.
26.
HowardRSLeesAJ. Encephalitis lethargica. A report of four recent cases. Brain. 1987;110(pt 1):19–33.
27.
DaleRCIraniSRBrilotF. N-methyl-d-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol. 2009;66:704–709.
28.
CretenCvan der ZwaanSBlankespoorRJ. Late onset autism and anti-NMDA-receptor encephalitis. Lancet. 2011;378:98.
29.
DhosscheDMWachtelLE. Catatonia is hidden in plain sight among different pediatric disorders: a review article. Pediatr Neurol. 2010;43:307–315.
30.
KolkerSChristensenELeonardJV. Diagnosis and management of glutaric aciduria type I—revised recommendations. J Inherit Metab Dis. 2011;34:677–694.
31.
KurianMAGissenPSmithMHealesSJrClaytonPT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011;10:721–733.
CorsellisJAGoldbergGJ, Norton AR. “Limbic encephalitis” and its association with carcinoma. Brain. 1968;91:481–496.
36.
TuzunEDalmauJ. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist. 2007;13:261–271.
37.
LaiMHuijbersMGLancasterE. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9:776–785.
38.
IraniSRAlexanderSWatersP. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133:2734–2748.
39.
VincentABuckleyCSchottJM. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127(pt 3):701–712.
AndradeDMTaiPDalmauJWennbergR. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?Neurology. 2011;76:1355–1357.
42.
LaiMHughesEGPengX. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65:424–434.
43.
LancasterELaiMPengX. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67–76.
44.
LancasterEMartinez-HernandezETitulaerMJ. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011;77:1698–1701.
45.
HaberlandtEBastTEbnerA. Limbic encephalitis in children and adolescents. Arch Dis Child. 2011;96:186–191.
46.
AkmanCIPattersonMCRubinsteinAHerzogR. Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency. Dev Med Child Neurol. 2009;51:563–567.
47.
CarrI. The Ophelia syndrome: memory loss in Hodgkin's disease. Lancet. 1982;1:844–845.
48.
GregoriosJBRoldanEDavisJCurlessR. Encephalomyelitis associated with leukemia in a child. J Child Neurol. 1987;2:293–297.
49.
MeyerJJBulteauCAdamsbaumCKalifaG. Paraneoplastic encephalomyelitis in a child with neuroblastoma. Pediatr Radiol. 1995;25(suppl 1):S99–S101.
50.
RosenbaumTGartnerJKorholzD. Paraneoplastic limbic encephalitis in two teenage girls. Neuropediatrics. 1998;29:159–162.
BergerICastielYDorT. Paediatric Hashimoto encephalopathy, refractory epilepsy and immunoglobulin treatment—unusual case report and review of the literature. Acta Paediatr. 2010;99:1903–1905.
53.
BektasOYilmazAKendirliTSiklarZDedaG. Hashimoto encephalopathy causing drug-resistant status epilepticus treated with plasmapheresis. Pediatr Neurol. 2012;46:132–135.
54.
Castro-GagoMGomez-LadoCManeiro-FreireMEiris-PunalJBravo-MataM. Hashimoto encephalopathy in a preschool girl. Pediatr Neurol. 2010;42:143–146.
55.
HoffmannFReiterKKlugerG. Seizures, psychosis and coma: severe course of hashimoto encephalopathy in a six-year-old girl. Neuropediatrics. 2007;38:197–199.
56.
TamagnoGCelikYSimoR. Encephalopathy associated with autoimmune thyroid disease in patients with Graves' disease: clinical manifestations, follow-up, and outcomes. BMC Neurol. 2010;10:27.
57.
TamagnoG. How should we denominate the encephalopathy occurring in patients with an autoimmune thyroid disease?Acta Paediatr. 2011;100:5–6.
58.
CastilloPWoodruffBCaselliR. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006;63:197–202.
59.
BohnenNIParnellKJHarperCM. Reversible MRI findings in a patient with Hashimoto's encephalopathy. Neurology. 1997;49:246–247.
60.
DoganMAcikgozEAcikgozMCesurYAriyucaSBektasMS. The frequency of Hashimoto thyroiditis in children and the relationship between urinary iodine level and Hashimoto thyroiditis. J Pediatr Endocrinol Metab. 2011;24:75–80.
61.
ZoisCStavrouIKalogeraC. High prevalence of autoimmune thyroiditis in schoolchildren after elimination of iodine deficiency in northwestern Greece. Thyroid. 2003;13:485–489.
62.
TuzunEErdagEDurmusH. Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis. Neurol India. 2011;59:47–50.
63.
BienCGGranataTAntozziC. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005;128(pt 3):454–471.
64.
HartYMAndermannFFishDR. Chronic encephalitis and epilepsy in adults and adolescents: a variant of Rasmussen's syndrome?Neurology. 1997;48:418–424.
65.
RogersSWAndrewsPIGahringLC. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science. 1994;265:648–651.
66.
DegenhardtADuvoisinRMFrennierJ. Absence of antibodies to non-NMDA glutamate-receptor subunits in paraneoplastic cerebellar degeneration. Neurology. 1998;50:1392–1397.
67.
Alvarez-BaronEBienCGSchrammJElgerCEBeckerAJSchochS. Autoantibodies to Munc18, cerebral plasma cells and B-lymphocytes in Rasmussen encephalitis. Epilepsy Res. 2008;80:93–97.
68.
BienCGBauerJDeckwerthTL. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol. 2002;51:311–318.
69.
GahringLCarlsonNGMeyerELRogersSW. Granzyme B proteolysis of a neuronal glutamate receptor generates an autoantigen and is modulated by glycosylation. J Immunol. 2001;166:1433–1438.
70.
BauerJElgerCEHansVH. Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann Neurol. 2007;62:67–80.
71.
ThiloBStingeleRKnudsenK. A case of Rasmussen encephalitis treated with rituximab. Nat Rev Neurol. 2009;5:458–462.
72.
DabbaghOGasconGCrowellJBamoggadamF. Intraventricular interferon-alpha stops seizures in Rasmussen's encephalitis: a case report. Epilepsia. 1997;38:1045–1049.
73.
MariaBLRingdahlDMMickleJP. Intraventricular alpha interferon therapy for Rasmussen's syndrome. Can J Neurol Sci. 1993;20:333–336.
74.
BienCGGleissnerUSassenRWidmanGUrbachHElgerCE. An open study of tacrolimus therapy in Rasmussen encephalitis. Neurology. 2004;62:2106–2109.
75.
BienCGSchrammJ. Treatment of Rasmussen encephalitis half a century after its initial description: promising prospects and a dilemma. Epilepsy Res. 2009;86:101–112.
76.
SakumaHAwayaYShiomiM. Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis. Acta Neurol Scand. 2010;121:251–256.
77.
vanBAStephaniUKlugerGHauslerMDulacO. FIRES: febrile infection responsive epileptic (FIRE) encephalopathies of school age. Brain Dev. 2009;31:91–93.
78.
MikaeloffYJambaqueIHertz-PannierL. Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis. Epilepsy Res. 2006;69:67–79.
79.
SpecchioNFuscoLClapsDVigevanoF. Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis. Brain Dev. 2010;32:51–56.
80.
CarranzaRDSimonHAIonaX. Febrile infection-related epilepsy syndrome is not caused by SCN1A mutations. Epilepsy Res. 2012;100:194–198.
81.
SuleimanJBrennerTGillD. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology. 2011;76:1252–1255.
82.
TateEDAllisonTJPranzatelliMRVerhulstSJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs. 2005;22:8–19.
83.
PranzatelliMRTateEDVerhulstSJ. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol. 2010;32:e167–e172.
84.
PranzatelliMRTravelsteadALTateEDAllisonTJVerhulstSJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord. 2004;19:770–777.
85.
AntunesNLKhakooYMatthayKK. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol. 2000;22:315–320.
86.
BlaesFFuhlhuberVKorfeiM. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol. 2005;58:313–317.
87.
KleinASchmittBBoltshauserE. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr. 2007;166:359–363.
88.
PohlKRPritchardJWilsonJ. Neurological sequelae of the dancing eye syndrome. Eur J Pediatr. 1996;155:237–244.
89.
Ize-LudlowDGrayJASperlingMA. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. Pediatrics. 2007;120:e179–e188.
90.
BougneresPPantaloneLLinglartARothenbuhlerALeSC. Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood. J Clin Endocrinol Metab. 2008;93:3971–3980.
91.
DePLTrochetDCaillat-ZucmanS. Delineation of late onset hypoventilation associated with hypothalamic dysfunction syndrome. Pediatr Res. 2008;64:689–694.
92.
NunnKOuvrierRSpragueTArbuckleSDockerM. Idiopathic hypothalamic dysfunction: a paraneoplastic syndrome?J Child Neurol. 1997;12:276–281.
93.
OuvrierRNunnKSpragueT. Idiopathic hypothalamic dysfunction: a paraneoplastic syndrome?Lancet. 1995;346:1298.
94.
HuppkePHeiseARostasyKHuppkeBGartnerJ. Immunoglobulin therapy in idiopathic hypothalamic dysfunction. Pediatr Neurol. 2009;41:232–234.
95.
Paz-PrielICookeDWChenAR. Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome. J Pediatr. 2011;158:337–339.
